Programmed death-ligand 1 (PD-L1) is an immune-related biomarker that can be expressed on the surface of many tissue types, including tumor cells. For certain types and stages of cancer, testing for PD-L1 expression may help to select patients most likely to benefit from treatment with PD-L1 inhibitors such as atezolizumab (TECENTRIQ), durvalumab (IMFINZI), nivolumab (OPDIVO), and pembrolizumab (KEYTRUDA). The specific test required for PD-L1 expression (eg, PD-L1 28-8, PD-L1 22C3, PD-L1 SP142, and PD-L1 SP263) depends on the tumor type and the specific inhibitor therapy being used.
Having trouble viewing the algorithm? Go directly to the PDF